MedWatch

Post-pandemic employee air travel clouds Novo Nordisk's climate report

Although ambitious climate targets have secured a spot for Novo Nordisk among the Danish companies that have gone the extra mile to curb climate change, the firm has faltered in the first half of 2022.

Photo: Mads Claus Rasmussen//

Few Danish companies have gone to the same lengths as Novo Nordisk when it comes to setting ambitious targets to reduce climate impact and, more importantly, actually doing the work needed to reach them, reports Danish business media Finans.

CO2 emissions from its operations and energy consumption were reduced by 42% between years 2019 and 2021, and in the same period the pharmaceutical firm managed to bring down its emissions related to business travel and transportation of goods by 44%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs